Momentum Watch: Key Drivers & Catalysts (HYZN, WINT, CELZ, LDTC, VLCN)
9/15/20246 min read
In the ever-evolving world of stock investments, uncovering the hidden gems among small-cap companies can often lead to significant returns. These smaller players in the market are fueled by a unique blend of key drivers and catalysts that can propel them to newfound heights. Today, we are highlighting five small-cap stocks, exploring the factors that unleash their potential and ignite investor interest.
Hyzon Motors Inc. (NASDAQ: HYZN) - Hyzon Motors Inc. shares closed last week slightly down, falling just under 2% to $2.25. Last month, the company reported its financial and operational results for the second quarter of 2024, along with key updates. In July, Hyzon launched a 200kW Class 8 Fuel Cell Electric Vehicle (FCEV) trial program with two major fleet operators. Additionally, a cross-continental refuse collection vehicle trial program is slated to begin this month. The company has shifted its focus to large fleet customers in the North American Class 8 and refuse markets, halting operations in the Netherlands and Australia to concentrate on regions with the highest immediate commercial potential. "In Q2 2024, we implemented several strategic initiatives, including concentrating our efforts on North American Class 8 and refuse markets, positioning ourselves to leverage commercial opportunities backed by U.S. government support," said Hyzon CEO Parker Meeks. "We launched the 200kW Class 8 vehicle trial in July, with the refuse vehicle trial set for later this month, which represents a crucial step toward securing long-term agreements with large fleets. Looking ahead to the second half of 2024, we anticipate reaching start of production (SOP) for our single-stack 200kW fuel cell system and Class 8 truck platform, building momentum for our decarbonization efforts and delivering long-term value for shareholders." As we await further updates, key levels to watch include a potential resistance break at $2.40 or a consolidation forming a bottom.
--
Windtree Therapeutics, Inc. (NASDAQ: WINT) - Windtree Therapeutics, Inc. shares closed last week up nearly 7%, reaching $3.17. This month, the company announced the successful completion of enrollment in its SEISMiC Extension Phase 2b study of istaroxime for early cardiogenic shock caused by heart failure. The study aims to evaluate istaroxime’s ability to improve heart function and stabilize low blood pressure in early cardiogenic shock due to heart failure. Windtree is hoping to build on the positive results seen in its initial SEISMiC Phase 2 study, which were previously reported. Additionally, the company is optimistic that the study will confirm earlier observations suggesting that istaroxime has a favorable renal profile and does not increase the risk of cardiac arrhythmias. The SEISMiC Extension Study includes longer dosing durations and a tapered dosing approach to assess these potential benefits. "Completing enrollment in the SEISMiC Extension Study is a significant milestone in advancing the istaroxime program toward Phase 3, alongside the ongoing SEISMiC Cstudy in patients with more severe cardiogenic shock," said Steve Simonson, MD, Chief Medical Officer and Senior Vice President of Windtree. "We expect to announce topline results from the SEISMiC Extension Study by the end of the month and plan to present this data at a major medical conference soon." As we await further developments, attention will be on a potential resistance break at $3.50. Additionally, it's worth noting that the company had both an S-1 and S-3 go into effect this month.
--
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) - Creative Medical Technology Holdings, Inc. shares closed last week at $3.25, up 7%. In July, the company provided a corporate update detailing recent developments. CEO Timothy Warbington reflected on 2024's achievements, attributing them to prior investments, a lean corporate structure, and strong partnerships that have facilitated the rapid advancement of novel therapies. In Q1 2024, the company received FDA Orphan Drug Designation for CELZ-101 (ImmCelz™), a therapy aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation—a significant advancement for those with brittle T1D, a condition marked by extreme blood glucose fluctuations. The company plans to file an IND for a Phase I/II clinical trial in the future. Additionally, in Q1 2024, the FDA authorized expanded access for CELZ-201, a pioneering cell-based therapy for managing abnormal glucose tolerance and preventing T1D in high-risk individuals. This marks the first time the FDA has authorized the use of proprietary cell-based biologics for disease prevention. The program received IRB approval and began patient recruitment during the first half of 2024. In July, the company also launched a program combining Artificial Intelligence (AI) with its proprietary human induced pluripotent stem cells (iPSCs) to diagnose and treat patients exposed to biological and chemical weapons. This is part of the iPSCelz® program. CEOTimothy Warbington will hold a call with RedChip Investor Group on September 24, 2024. As we await further updates, we are watching for a potential resistance break at $3.50 with increased volume.
--
LeddarTech Holdings Inc. (NASDAQ: LDTC) - LeddarTech Holdings Inc. shares fell nearly 2% last week, closing at $0.44. In August, the company announced significant progress with OEM and Tier 1 automotive customers, improved software maturity, and extended feature performance with key partners like Arm and Texas Instruments. "The automotive industry is increasingly recognizing the maturity of our LeddarVision software for fusion and perception, which helps automakers meet and exceed customer and regulatory demands for ADAS and autonomous driving," said Frantz Saintellemy, LeddarTech's President and CEO. LeddarTech will showcase its automotive software technology at Autosens Europe, October 8-10, 2024, in collaboration with Ficosa. The company also secured up to US$9 million in financing and announced US$1.5 million of convertible note conversions above market at $2.00 per share. As we await further updates, key levels to watch include a potential resistance break at $0.48. Additionally noting, the company's F-1/A filing is still pending approval.
--
Volcon Inc. (NASDAQ: VLCN) - Volcon Inc.'s shares closed last week’s trading session up nearly 1%, ending at $1.27. In early August, the company shared its operational highlights and financial results for the quarter ending June 30, 2024. In May, Volcon shipped three additional Stags to the Army Corps and expects to complete the remaining deliveries by August 2024, a month later than the originally planned July 2024 shipment due to manufacturing delays caused by the late availability of certain components. The manufacturer has finished the units, which are now awaiting final quality inspection. Volcon also signed an agreement with a manufacturer to develop and produce the next-generation Grunt, with prototypes expected by Q3 2024. Additionally, the company entered into an agreement with a UTV manufacturer to distribute a new utility UTV model in North America. This UTV will feature a single-row bench seat and a dump bed. The manufacturer is also licensed to sell this model outside of North America under the Volcon brand, with Volcon receiving a royalty on each unit sold starting in year three of the agreement. Prototypes of this UTV are also expected by Q3 2024. As we await further updates, we are closely monitoring a resistance level break at $1.35, especially if accompanied by increased trading volume.
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.